Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond

OBJECTIVES: Tofacitinib is an oral Janus kinase inhibitor for treatment of psoriatic arthritis (PsA). Patient-reported outcomes (PROs) were evaluated in patients with PsA with inadequate responses to tumour necrosis factor inhibitors (TNFi-IR) in a 6-month, phase III randomised controlled trial (OPA...

Descripción completa

Detalles Bibliográficos
Autores principales: Strand, Vibeke, de Vlam, Kurt, Covarrubias-Cobos, Jose A, Mease, Philip J, Gladman, Dafna D, Chen, Linda, Kudlacz, Elizabeth, Wu, Joseph, Cappelleri, Joseph C, Hendrikx, Thijs, Hsu, Ming-Ann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Psoriatic Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340607/
https://www.ncbi.nlm.nih.gov/pubmed/30713722
http://dx.doi.org/10.1136/rmdopen-2018-000808

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340607/
https://www.ncbi.nlm.nih.gov/pubmed/30713722
http://dx.doi.org/10.1136/rmdopen-2018-000808

Ejemplares similares